<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39334459</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1525-139X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Seminars in dialysis</Title><ISOAbbreviation>Semin Dial</ISOAbbreviation></Journal><ArticleTitle>Increase of Hepatitis B Surface Antibody Levels After Inactivated COVID-19 Vaccine in Hemodialysis Patients: An Important Single-Center Observation.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/sdi.13229</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The effects of COVID-19 vaccines on immunocompromised people such as hemodialysis (HD) patients are an important topic that should be addressed. This study reports an observation of the effect of the third dose of the Sinopharm vaccine (SphV3) on the level of hepatitis B surface antibody (anti-HBs) in HD patients, and the differences between anti-HBs titers before and after SphV3 were analytically evaluated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-center observational study involved all HD patients presented to Shariati Hospital, Tehran, Iran, from February 2021 to March 2022. All patients received three doses of the Sinopharm vaccine over 8 months. The anti-HBs level is measured every 6 months as the routine evaluation against HBV infection for all HD patients. Three months before (anti-HBs-B3) and 3 months after (anti-HBs-A3) SphV3 were the routine times to measure the anti-HBs titer during this study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-five HD patients were enrolled. Overall, the anti-HBs-A3 was significantly higher than anti-HBs-B3 (p = 0.001). The anti-HBs levels before and after SphV3 were not statistically remarkable in patients with diabetes and ischemic heart disease. The patients with a history of kidney transplant and those with a history of COVID-19 had significant differences between anti-HBs-B3 and anti-HBs-A3 (p = 0.002, p = 0.003, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings revealed that inactivated COVID-19 vaccine may be involved in the humoral immune response to hepatitis B in HD patients. It may be novel and have significant implications for the vaccination protocol for immunocompromised patients, including those undergoing HD and transplant recipients.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaghoubi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3120-7111</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalil</LastName><ForeName>Davood</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iranzadeh</LastName><ForeName>Saeid</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghahramani</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Student Research Committee, Faculty of Medicine, Shahed University, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Semin Dial</MedlineTA><NlmUniqueID>8911629</NlmUniqueID><ISSNLinking>0894-0959</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 vaccine</Keyword><Keyword MajorTopicYN="N">Sinopharm</Keyword><Keyword MajorTopicYN="N">hemodialysis</Keyword><Keyword MajorTopicYN="N">hepatitis B</Keyword><Keyword MajorTopicYN="N">hepatitis B surface antigens</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39334459</ArticleId><ArticleId IdType="doi">10.1111/sdi.13229</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>S. Udomkarnjananun, K. Takkavatakarn, K. Praditpornsilpa, et al., “Hepatitis B Virus Vaccine Immune Response and Mortality in Dialysis Patients: A Meta‐Analysis,” Journal of Nephrology 33 (2020): 343–354.</Citation></Reference><Reference><Citation>M. Buti, L. Viladomiu, R. Jardi, et al., “Long‐Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Hemodialysis Patients,” American Journal of Nephrology 12, no. 3 (1992): 144–147.</Citation></Reference><Reference><Citation>F. Fabrizi, V. Dixit, P. Martin, M. Jadoul, and P. Messa, “Meta‐Analysis: The Impact of Nutritional Status on the Immune Response to Hepatitis B Virus Vaccine in Chronic Kidney Disease,” Digestive Diseases and Sciences 57 (2012): 1366–1372.</Citation></Reference><Reference><Citation>T. Nopsopon, J. Kittrakulrat, K. Takkavatakarn, T. Eiamsitrakoon, T. Kanjanabuch, and K. Pongpirul, “Covid‐19 in End‐Stage Renal Disease Patients With Renal Replacement Therapies: A Systematic Review and Meta‐Analysis,” PLoS Neglected Tropical Diseases 15, no. 6 (2021): e0009156.</Citation></Reference><Reference><Citation>A. Francis, C. Baigent, T. A. Ikizler, P. Cockwell, and V. Jha, “The Urgent Need to Vaccinate Dialysis Patients Against Severe Acute Respiratory Syndrome Coronavirus 2: A Call to Action,” Kidney International 99, no. 4 (2021): 791–793.</Citation></Reference><Reference><Citation>J. Alderson, V. Batchelor, M. O'Hanlon, et al., “Overview of Approved and Upcoming Vaccines for SARS‐CoV‐2: A Living Review,” Oxford Open Immunology 2, no. 1 (2021): iqab010.</Citation></Reference><Reference><Citation>U. Sahin, A. Muik, E. Derhovanessian, et al., “COVID‐19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses,” Nature 586, no. 7830 (2020): 594–599.</Citation></Reference><Reference><Citation>F. Yaghoubi and D. Dalil, “Acquired Thrombotic Thrombocytopenic Purpura After AstraZeneca Vaccine: A Case Report,” Caspian Journal of Internal Medicine 13, no. Suppl 3 (2022): 299–302, https://doi.org/10.22088/cjim.13.0.299.</Citation></Reference><Reference><Citation>M. Aoun, R.‐M. Kahwaji, G. Sleilaty, et al., “Factors Predictive of Anti‐spike Antibody Titers After COVID‐19 Vaccination in Hemodialysis Patients,” Advances in Clinical and Experimental Medicine 31, no. 8 (2022): 855–861.</Citation></Reference><Reference><Citation>C. Danthu, S. Hantz, A. Dahlem, et al., “Humoral Response After SARS‐CoV‐2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients,” Journal of the American Society of Nephrology: JASN 32, no. 9 (2021): 2153–2158.</Citation></Reference><Reference><Citation>A. Murt, M. R. Altiparmak, D. Ozbey, et al., “Antibody Responses to Inactivated SARS‐CoV‐2 Vaccine in Peritoneal Dialysis Patients,” Seminars in Dialysis 35, no. 3 (2022): 264–268, https://doi.org/10.1111/sdi.13049.</Citation></Reference><Reference><Citation>N. Nacasch, K. Cohen‐Hagai, N. Tayar, et al., “Humoral Response to Hepatitis B and COVID‐19 Vaccine Among Maintenance Hemodialysis Patients,” Vaccine 10, no. 10 (2022): 1670.</Citation></Reference><Reference><Citation>B. Simon, H. Rubey, A. Treipl, et al., “Haemodialysis Patients Show a Highly Diminished Antibody Response After COVID‐19 mRNA Vaccination Compared With Healthy Controls,” Nephrology, Dialysis, Transplantation 36, no. 9 (2021): 1709–1716.</Citation></Reference><Reference><Citation>J. Stumpf, T. Siepmann, T. Lindner, et al., “Humoral and Cellular Immunity to SARS‐CoV‐2 Vaccination in Renal Transplant Versus Dialysis Patients: A Prospective, Multicenter Observational Study Using mRNA‐1273 or BNT162b2 mRNA Vaccine,” Lancet Regional Health–Europe 9 (2021): 100178, https://doi.org/10.1016/j.lanepe.2021.100178.</Citation></Reference><Reference><Citation>J. Wellenkötter, M. Anft, K. Paniskaki, et al., “SARS‐CoV‐2 Vaccination Improves HBV Seroconversion Rate Through Heterological Immunity,” Kidney International 103, no. 1 (2023): 223–225, https://doi.org/10.1016/j.kint.2022.10.012.</Citation></Reference><Reference><Citation>S. Cai, G. Liao, T. Yu, et al., “Immunogenicity and Safety of an Inactivated SARS‐CoV‐2 Vaccine in People Living With HIV: A Cross‐Sectional Study,” Journal of Medical Virology 94, no. 9 (2022): 4224–4233.</Citation></Reference><Reference><Citation>B. Agrawal, “Heterologous Immunity: Role in Natural and Vaccine‐Induced Resistance to Infections,” Frontiers in Immunology 10 (2019): 2631.</Citation></Reference><Reference><Citation>N. Le Bert, A. T. Tan, K. Kunasegaran, et al., “SARS‐CoV‐2‐Specific T Cell Immunity in Cases of COVID‐19 and SARS, and Uninfected Controls,” Nature 584, no. 7821 (2020): 457–462.</Citation></Reference><Reference><Citation>A. Grifoni, D. Weiskopf, S. I. Ramirez, et al., “Targets of T Cell Responses to SARS‐CoV‐2 Coronavirus in Humans With COVID‐19 Disease and Unexposed Individuals,” Cell 181, no. 7 (2020): 1489–1501.e15.</Citation></Reference><Reference><Citation>J. Braun, L. Loyal, M. Frentsch, et al., “SARS‐CoV‐2‐Reactive T Cells in Healthy Donors and Patients With COVID‐19,” Nature 587, no. 7833 (2020): 270–274.</Citation></Reference><Reference><Citation>J. Mateus, A. Grifoni, A. Tarke, et al., “Selective and Cross‐Reactive SARS‐CoV‐2 T Cell Epitopes in Unexposed Humans,” Science 370, no. 6512 (2020): 89–94.</Citation></Reference><Reference><Citation>P. J. Eggenhuizen, B. H. Ng, J. Chang, et al., “BCG Vaccine Derived Peptides Induce SARS‐CoV‐2 T Cell Cross‐Reactivity,” Frontiers in Immunology 12 (2021): 692729.</Citation></Reference><Reference><Citation>P. J. Eggenhuizen, B. H. Ng, J. Chang, et al., “Heterologous Immunity Between SARS‐CoV‐2 and Pathogenic Bacteria,” Frontiers in Immunology 13 (2022): 821595, https://doi.org/10.3389/fimmu.2022.821595.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>